EuroBiotech: More Articles of Note

(NS Newsflash/CC BY 2.0)

> Vernalis paid £10 million ($13 million) to terminate its agreement with Tris Pharma. The decision follows regulatory setbacks for products covered by the agreement. Release (PDF)

> Syncona founded two gene therapy startups. The British life science investor committed $23 million to SwanBio and $12 million to Orbit Biomedical. Statement (PDF)

> Newron Pharmaceuticals delayed a readout from its phase 3 Rett syndrome clinical trial by up to six months. Statement

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

> PharmaMar asked to change the primary endpoint of its phase 3 lung cancer trial. Moving from progression-free to overall survival will delay the readout until the second half of next year. Release (PDF)

> Motif Bio completed the rolling NDA for its antibiotic iclaprim. Statement

Suggested Articles

Cold Genesys is developing its lead asset as a single agent and in combination therapies and has taken it through phase 2 in bladder cancer.

Dermira has generated evidence that its treatment for moderate-to-severe atopic dermatitis can pose a challenge to Regeneron and Sanofi’s Dupixent.

Shares in Aerpio Pharmaceuticals were more than halved in early trading this morning after it announced the failure of its leading drug candidate.